...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncogene >Bevacizumab in the treatment of non-small-cell lung cancer
【24h】

Bevacizumab in the treatment of non-small-cell lung cancer

机译：贝伐单抗治疗非小细胞肺癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced disease, and treatment with standard cytotoxic chemotherapy improves survival and quality of life in patients with a preserved functional status. However, the prognosis is poor with the majority of patients dying in less than a year. Treatment with standard cytotoxic chemotherapy has reached a therapeutic plateau, and new therapeutic approaches have investigated therapies that target the specific molecular pathways involved in carcinogenesis and angiogenesis. The most promising strategy for inhibiting angiogenesis involves agents that either target the proangiogenesis growth factor, vascular endothelial growth factor A (VEGF) by preventing binding to the receptor or inhibiting the downstream signaling of the vascular endothelial growth factor receptor. The only therapeutic agent approved for the treatment of lung cancer is bevacizumab, a monoclonal antibody that binds to VEGF. A recent phase III trial revealed a statistically significant improvement in response rate, progression free and overall survival with combination of bevacizumab with chemotherapy over chemotherapy alone. Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents.
机译：肺癌是美国癌症死亡的主要原因。大多数患者患有晚期疾病，并且通过标准的细胞毒性化学疗法进行治疗可以改善功能状态保持不变的患者的生存率和生活质量。但是，预后很差，大多数患者在不到一年的时间内死亡。用标准细胞毒性化学疗法进行的治疗已达到治疗平台，并且新的治疗方法已研究出针对与癌变和血管生成有关的特定分子途径的疗法。抑制血管生成的最有希望的策略涉及通过阻止与受体结合或抑制血管内皮生长因子受体的下游信号传导而靶向血管生成生长因子，血管内皮生长因子A（VEGF）的药物。批准用于治疗肺癌的唯一治疗剂是贝伐单抗，这是一种与VEGF结合的单克隆抗体。最近的一项III期临床试验表明，贝伐单抗联合化疗联合化疗比单纯化疗具有更高的应答率，无进展和总体生存率的统计学意义。目前正在尝试鉴定抗血管生成活性的替代标记，并且可能有助于选择抗血管生成治疗的患者以及开发这类药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号